Skip to content
DataLookout
Menu

DOMMINO-2NCT07772024

Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 1 version: 1 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 1 → 11 locations
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Progression-free Survival (PFS) assessed by Blinded Independent Central Review (BICR)
Timeframe: From randomization until progressive disease or death, assessed every 28 days and followed until the final PFS analysis after approximately 330 PFS events; estimated up to approximately 38 months after the start of enrollment
Objective Response Rate (ORR) assessed by BICR
Timeframe: From randomization until confirmed progressive disease, initiation of subsequent anticancer therapy, death, withdrawal, or the ORR data cutoff, whichever occurs first; disease response assessed every 28 days (up to 48 months)

Secondary (22)

Overall Survival (OS)
PFS Assessed by the Investigator
ORR Assessed by the Investigator
Minimal Residual Disease (MRD) Negativity Rate
Duration of Response (DoR) Assessed by BICR
Show 17 moreShow less
DoR Assessed by the Investigator
Time to Response (TTR) Assessed by BICR
TTR Assessed by the Investigator
Very Good Partial Response (VGPR) or Better Rate Assessed by BICR
VGPR or Better Rate Assessed by the Investigator
Complete Response (CR) or Better Rate Assessed by BICR
CR or Better Rate Assessed by the Investigator
Change From Baseline in EORTC QLQ-C30 Scores
Change From Baseline in EORTC QLQ-MY20 Disease Symptoms Score
Change From Baseline in EQ-5D-5L Health Status
Treatment Side-Effect Bother Assessed by FACT-GP5
Symptomatic Adverse Events Assessed by PRO-CTCAE
Participants With Treatment-Emergent Adverse Events
Change From Baseline in Electrocardiogram Parameters
Change From Baseline in Vital Signs
Participants With Laboratory Abnormalities
Plasma Concentrations of Inobrodib

Arms and interventions

InoPdExperimental

Inobrodib in combination with pomalidomide and dexamethasone

Investigator's choice of Standard Available TherapyActive comparator

Investigator's choice of elotuzumab in combination with pomalidomide and dexamethasone (EPd), daratumumab in combination with pomalidomide and dexamethasone (DPd), or carfilzomib in combination with dexamethasone (Kd).

Drugs: InoPd, Investigator's choice of SAT

Sites

11 sites in 1 country